Table 3: Cox proportional hazards analysis of the biological and clinicopathological features of prostate cancer predicting OS in localized PCa patients.

Variable

Univariate analysis

Multivariate analysis

RR

95% CI

p value*

RR

95% CI

value

Age (years)

 

 

 

 

 

 

≤ 59.0

1.00

Reference

 

 

 

 

> 59.0

1.33

0.72-2.44

0.356

 

 

 

PSA

 

 

 

 

 

 

≤ 9.2 ng/mL

1.00

Reference

 

 

 

 

> 9.2 ng/mL

1.37

0.81-2.33

0.239

 

 

 

AJCC Grade

 

 

 

 

 

 

1-3

1.00

Reference

 

 

 

 

4

1.55

0.66-3.61

0.313

 

 

 

Clinical stage

 

 

 

 

 

 

cT1-2

1.00

Reference

0.363

 

 

 

cT3-4

1.28

0.75-2.19

 

 

 

 

Pathological stage

 

 

 

 

 

 

pT1-2

1.00

Reference

 

 

 

 

pT3-4

1.28

0.75-2.19

0.357

 

 

 

Radical surgery

 

 

 

 

yes

0.70

0.41-1.19

0.186

 

 

 

no

1.00

Reference

 

 

 

 

Hist-pat surgical margins

 

 

 

 

 

 

negative

1.00

Reference

 

 

 

 

positive

1.16

0.68-1.97

0.590

 

 

 

Seminal vesicle(s) invasion

 

 

 

 

 

 

negative

0.92

0.45-1.89

0.833

 

 

 

positive

1.00

Reference

 

 

 

 

Adjuvant treatment

 

 

 

 

 

 

no

1.00

Reference

0.078

1.00

Reference

 

yes

0.61

0.35-1.06

 

0.48

0.27-0.86

0.013

Ki-67LI

 

 

 

 

 

 

≤ 6.7 %

1.00

Reference

 

1.00

Reference

 

> 6.7 %

1.58

0.93-2.68

0.089

2.04

1.18-3.54

0.010

GLUT-1LI

 

 

 

 

 

 

≤ 1.4 %

1.00

Reference

 

 

 

 

> 1.4 %

2.78

1.00-7.73

0.049

 

 

 

VEGF LI

 

 

 

 

 

 

≤ 16.3 %

1.00

Reference

 

 

 

 

> 16.3 %

0.63

0.36-1.12

0.119

 

 

 

MVD

 

 

 

 

 

 

≤ 84.2/mm2

1.00

Reference

 

 

 

 

> 84.2/mm2

1.23

0.69-2.21

0.470

 

 

 

PSMA LI

 

 

 

 

 

 

≤ 51.7 %

1.00

Reference

 

1.00

Reference

 

> 51.7 %

0.47

0.26-0.87

0.016

0.43

0.23-0.81

0.009

hTERT LI

 

 

 

 

 

 

≤ 20.5 %

1.00

Reference

 

1.00

Reference

 

> 20.5%

0.49

0.27-0.91

0.023

0.39

0.21-0.75

0.004

RR: risk ratio, CI: confidence interval.